Journal issues > Issue 4, June 2024 > Novel JAK inhibitors for the treatment of myelofibrosis

Novel JAK inhibitors for the treatment of myelofibrosis

SUMMARY

Myelofibrosis (MF) is a rare Philadelphia chromosome negative myeloproliferative bone marrow disorder characterised by a high symptom burden due to splenomegaly, inflammatory status and cytopenias. Until recently, the only approved and reimbursed pharmacotherapy for non-haematopoietic stem cell transplant candidates in Belgium was ruxolitinib. However, as of September 1^st, 2023, the novel JAK (janus kinase) 1/2 inhibitor (JAKi) fedratinib has obtained its reimbursement in second line. The other FDA approved JAKi, momelotinib and pacritinib, play an important role in patient-tailored JAKi treatment but are not yet reimbursed in Belgium.

(BELG J HEMATOL 2024;15(4):165–71)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top